ProCE Banner Series

Continued Evolution of Immunotherapy-Based Treatment in NSCLC: Multidisciplinary Perspectives for Clinical Practice

Discover the latest advancements in managing lung cancer with immunotherapy at our CME/CPE/CE-certified meeting series. Join us to stay at the forefront of cutting-edge treatments and insights!

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for oncology physicians, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with lung cancer.

All Events

Upcoming Events

February

26

2024

Continued Evolution of Immunotherapy-Based Treatment in NSCLC: Multidisciplinary Perspectives for Clinical Practice [Open Registration]

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group SC, Columbia, South Carolina

Past Events

January

24

2024

Continued Evolution of Immunotherapy-Based Treatment in NSCLC: Multidisciplinary Perspectives for Clinical Practice

8:00 AM - 9:00 AM Central Time (CT)

Virtual

Virtual Event | Host Group in IL, Hazel Crest, Illinois

January

25

2024

Continued Evolution of Immunotherapy-Based Treatment in NSCLC: Multidisciplinary Perspectives for Clinical Practice

8:15 AM - 9:15 AM Eastern Time (ET)

Virtual

Private Event, Bennington, Vermont

Faculty

ProCE Banner Faculty
Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

ProCE Banner Faculty
Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Topics

Overview of Immunotherapy in Resectable Nonmetastatic NSCLC

  • Current role of immunotherapy in the treatment algorithm for resectable nonmetastatic NSCLC
  • Optimal use of immunotherapy in resectable stage I-III NSCLC
  • Neoadjuvant and adjuvant immunotherapy in early-stage NSCLC
  • Sequencing: How do you manage patients with recurrent disease after receiving ICIs for nonmetastatic disease?
  • Immune resistance and expanding role of immunotherapy combinations

Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC

  • Current immunotherapy landscape and practice-changing clinical trials in stage III unresectable and metastatic NSCLC (ICI-naive patients or previous ICI exposure)
  • Clinical factors influencing response to ICIs
  • When to use ICI monotherapy and when to combine with chemotherapy, radiation, or other therapies
  • Therapy after first-line ICIs with or without chemotherapy

Optimizing Supportive Care Within the Multidisciplinary Team

  • Managing immune-related adverse events (irAEs)
  • Distinguishing irAEs from chemotherapy and targeted therapy AEs with combination therapy and appropriate management

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of the oncology multidisciplinary care team to apply available clinical data on novel and emerging immunotherapies to individualize care for patients with non-small cell lung cancer. 

Target Audience
This educational program is intended for oncology physicians, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with lung cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with stage IB-IIIA NSCLC who will benefit from ICI-based therapy, considering current indications, available evidence, and expert recommendations
  • Select optimal ICI-based regimens for patients with advanced/metastatic NSCLC
  • Develop multidisciplinary team strategies to effectively manage AEs associated with ICI-based therapies in patients with NSCLC while maintaining the most effective treatment regimens

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-030-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.